Rituximab cut MS relapses; infections rose after switch
Key Takeaway
People taking rituximab had fewer MS relapses, but those who switched to it had more serious infections.
What They Found
Disability worsened at similar rates with rituximab and approved MS treatments. After three years, about 9% of people who started with rituximab had worsening disability. About 5% of those who switched to rituximab had worsening disability. People taking rituximab had fewer relapses and were more likely to stay on treatment. Infections needing hospital care were more common after switching to rituximab, but not when it was the first treatment.
Who Should Care and Why
The study followed adults in Sweden with relapsing-remitting MS who started or switched treatment. It compared rituximab with approved MS treatments. The findings are relevant to people weighing relapse control against infection risk. Disability worsening was mostly unrelated to relapses among people taking rituximab. Scores for the physical and emotional impact of MS improved slightly with rituximab and were mostly similar across treatments.
Important Considerations
Researchers observed 2,449 people starting their first treatment and 2,463 switching treatments. You should know this was an observational study, not a trial that assigned treatments. Researchers accounted for health differences, but the study cannot prove rituximab caused the outcomes.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/9/2026
A mouse study suggests prepared red blood cells may calm MS-like immune attacks. Learn why liver cel
Read More
10/9/2026
See how lab-grown nerve cells move a key protein, why this may matter for nerve health, and why the
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.